INTEGRATED BIOPHARMA INC — Revenue by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a4998fb3-24b0-4cdf-98e1-48391fc05c9d/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $54.4M | 2024-07-01 – 2025-06-30 | evidence 0001437749-25-029711 |
| FY 2024 | $50.3M | 2023-07-01 – 2024-06-30 | evidence 0001437749-24-029768 |
| FY 2023 | $50.7M | 2022-07-01 – 2023-06-30 | evidence 0001437749-23-026022 |
| FY 2022 | $56.2M | 2021-07-01 – 2022-06-30 | evidence 0001437749-22-022334 |
| FY 2021 | $63.6M | 2020-07-01 – 2021-06-30 | evidence 0001437749-21-021375 |
| FY 2020 | $52.8M | 2019-07-01 – 2020-06-30 | evidence 0001437749-20-020123 |
| FY 2019 | $50.0M | 2018-07-01 – 2019-06-30 | evidence 0001437749-19-017611 |
| FY 2018 | $43.7M | 2017-07-01 – 2018-06-30 | evidence 0001437749-19-017611 |
| FY 2017 | $31.1M | 2017-04-01 – 2018-03-31 | evidence 0001437749-18-009219 |
| FY 2016 | $35.7M | 2016-04-01 – 2017-03-31 | evidence 0001437749-18-009219 |
| FY 2015 | $37.5M | 2014-07-01 – 2015-06-30 | evidence 0001016504-15-000010 |
| FY 2014 | $33.7M | 2013-07-01 – 2014-06-30 | evidence 0001016504-15-000010 |
| FY 2013 | $33.6M | 2012-07-01 – 2013-06-30 | evidence 0001016504-13-000011 |
| FY 2012 | $36.6M | 2011-07-01 – 2012-06-30 | evidence 0001016504-12-000022 |
| FY 2011 | $40.7M | 2010-07-01 – 2011-06-30 | evidence 0001016504-12-000022 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
INTEGRATED BIOPHARMA INC — all facts · Net Income · Operating Income